FT : EY reaches deal to give staff legal protection during Wirecard inquiry

EY reaches deal to give staff legal protection during Wirecard inquiry
Auditor of collapsed payments group seeking assurances that staff will not be breaking laws by revealing details of work

EY has reached a deal with German politicians to give its auditors protection from the legal risk of giving evidence at a Wirecard inquiry and warned its staff to prepare for more fallout from hearings taking place this week.

The German parliamentary inquiry committee has called several senior managers from the Big Four firm to give evidence at its inquiry into the high-profile collapse of the payments group. EY audited the group for more than a decade and had questioned how its senior staff could adhere to client privacy rules if they had to reveal details.

Wirecard’s administrator has released EY partners from all confidentiality obligations but, in the past, some German courts ruled that such a waiver was not sufficient.

According to people with direct knowledge of the matter, the parliamentary inquiry committee and EY informally agreed to seek a clarification from Germany’s federal court of justice to allow EY staff to reveal previously confidential details about their work for Wirecard without breaking any rules.

In the informal deal, EY partners will on Thursday decline to testify and will be issued with a fine by the committee. The witnesses will then challenge the fine at the federal court, which will decide if the administrator’s waiver is sufficient.

“We fully understand that the witnesses do not want to face the risk of a criminal investigation should they violate their confidentiality duties by giving testimony,” Kay Gottschalk, a politician for far-right Alternative für Deutschland and the chairman of the inquiry committee, told the Financial Times, adding that he hoped for a swift court decision.

Last week, Wirecard’s former chief executive Markus Braun caused a stir by refusing to answer even basic questions from MPs, citing his right to remain silent.

EY has been criticised for its repeated failures to spot problems at Wirecard. It faces a number of investor lawsuits over the scandal and has already lost two clients, DWS and Commerzbank, as a result.

The committee has summoned EY partners Martin Dahmen and Christian Orth as well as Deutsche Bank’s head of accounting Andreas Loetscher, who left EY in 2018.

On Monday, the firm said its staff were willing to give full evidence in parliament only if they were sure that they were legally allowed to do so.

It added that the “legal situation was controversial”, pointing to past rulings by German courts concluding that a waiver by the administrator was “not sufficient” and needed to be granted by the company’s management or supervisory board instead. At Wirecard, both bodies ceased to exist this summer.

Andy Baldwin, EY’s global managing partner for client service, said: “EY is fully supportive of all official investigations and inquiries including those by the German Bundestag. We are hopeful that the witnesses invited in a personal capacity can be fully released from confidentiality so they can best assist the inquiry.”

EY said it had taken this position because of the “high criminal and professional risks” for auditors. “Violations may result in imprisonment of up to a year or fines of up to €10m,” the firm said.

“The predominant majority of court rulings asserts that the administrator is able to waive the confidentiality. We think that it is extremely important that EY testifies, also in its self-interest,” said Florian Toncar, a MP for the liberal Free Democrats (FDP).

An internal email sent to EY partners this weekend also revealed that the firm is braced for the testimony of a number of partners from KPMG, which was hired by Wirecard’s supervisory board to do a special audit of the group after allegations reported by the Financial Times.

The email said that “not all of KPMG’s findings have been made public to date” and said it expects “negative comments . . . related to EY Germany’s audit work” during the KPMG witness evidence.

EY said it would provide EY partners with “talking points” for their clients “once we know the scope of KPMG’s testimony”.

“We expect to see continuing media coverage on EY, and it is important that we remain proactive in having conversations with clients,” the EY email to partners said. “Please remember that this is an isolated incident, and we must not let it detract . . . from the resilience of our global network.”

CNBC : Peter Thiel backs Berlin start-up making psychedelics in $125 million rou

Peter Thiel backs Berlin start-up making psychedelics in $125 million round


  • Peter Thiel has led a $125 million funding round into a start-up aiming to make psychedelic drugs to treat mental health disorders.
  • Total investment in the company now stands at over $210 million.
  • Almost a billion people suffer from mental health problems worldwide, according to the World Health Organization.

LONDON — Billionaire tech investor Peter Thiel has backed a Berlin start-up aiming to make psychedelic drugs to treat mental health disorders in a $125 million funding round.

ATAI Life Sciences, which describes itself as a drug development platform, was set up to acquire, incubate and develop psychedelics and other drugs that can be used to treat depression, anxiety, addiction and other mental health conditions. The company — founded in 2018 by entrepreneurs Christian Angermayer, Florian Brand, Lars Wilde and Srinivas Rao — announced the funding on Monday.

“ATAI’s great virtue is to take mental illness as seriously as we should have been taking all illness all along,” Thiel, who co-founded Palantir and PayPal, said in a statement shared with CNBC. “The company’s most valuable asset is its sense of urgency.”

Thiel made a 10 million euro ($12 million) investment in ATAI through his venture firm, Thiel Capital, while the rest of the series C funding round came from Apeiron Investment Group (Angermayer’s family office), Catalio Capital Management, Future Ventures, Galaxy Investment Partners, Falcon Edge Capital, and Pura Vida.

Total investment in the company now stands at over $210 million.

ATAI, which has roughly 35 staff in offices across Berlin, New York and San Diego, is currently partnered with around 10 drug development companies. In exchange for a majority stake in the drugs they’re developing, ATAI helps the scientists to raise money, work with the regulators, and conduct clinical trials.

None of ATAI’s drugs have been formally approved by regulators to date.

There is growing interest in certain psychedelics after recent clinical studies suggested that some could help patients with a number of mental illnesses, either in combination with traditional solutions or in cases where nothing else has worked.

“The current treatments (for mental health issues) which are out there are definitely not sufficient,” company co-founder Angermayer told CNBC via Zoom ahead of the announcement. “I don’t want to say they don’t work as all because some people are helped by them but they’re not sufficient.”

Almost a billion people suffer from mental health problems worldwide, according to the World Health Organization. Of the 322 million people globally that have depression, roughly a third are treatment-resistant, according to fellow company co-founder Brand.

ATAI said it will use the new funding to pay for the clinical development of drugs that ATAI has already backed. This includes ar-ketamine, which is being developed at Perception Neuroscience for treatment-resistant depression, and ibogaine, which is being developed by DemeRx to treat opioid addiction. The funding will also be used to identify new drugs and support their development.

Earlier this year, the U.S. Food and Drug Administration approved Johnson & Johnson’s ketamine-like nasal spray for depression and there are a number of other start-ups trying to get psychedelic drugs to market including MindMed and Beckley Psytech.

Psychedelic trips
Angermayer said that people “meet themselves” when they have a psychedelic trip. “Since we’re born, society imposes on us how we should be, what we should look like, what we should wear/do/say,” he said. “We put a lot of camouflage on our soul, on our character, on our inner self. Psychedelics take away all these things which were imposed on us. That is an extremely important thing because I am very convinced you need to know yourself.”

Angermayer said he is confident that ATAI’s drugs work in principal when it comes to treating mental health problems, but acknowledges there are hurdles to overcome. “Drug development unfortunately is not just science,” he said. “Even if things work, you can still mess it up with the wrong trial design, or there can be political hurdles. But I am confident we are well on track.”

Rao, who is the company’s chief scientific officer, told CNBC via Zoom that ATAI was going through all the necessary regulatory processes to ensure their drugs were fully legal. “We’re not doing plants and we’re not doing extracts,” he said. “We’re doing synthetic or semi-synthetic.”

Rao said the company would begin by focusing on the U.S., adding that it represents around 50% of the world’s pharmaceutical market. “That is the obvious place to start,” he said.

Compass Pathways
ATAI has also invested in Compass Pathways, which has developed a synthetic version of the active ingredient in magic mushrooms, psilocybin.

Compass Pathways, which Thiel has also invested in, listed on the New York’s NASDAQ stock exchange in September and now has a valuation of around $1.3 billion. ATAI’s owns roughly 25% of Compass Pathways.

The plan is to take ATAI public next year at a valuation of between $1 and $2 billion, according to an industry source that asked to remain anonymous due to the nature of the discussions.

In reference to the future of ATAI, Brand added: “I would say we have all avenues open right now and haven’t yet finally decided which one we will take.”

WSJ : Shooting Has Never Been So Valuable in the NBA

Shooting Has Never Been So Valuable in the NBA
Joe Harris, Davis Bertans and Fred VanVleet were the big winners of free agency. It’s a bull market for the league’s best shooters.

The most demoralizing experiences for an NBA player include getting surgery, getting traded by a good team and getting waived by a bad team. Joe Harris experienced all three on the same day in 2016.

At that point of his basketball career, Harris didn’t know if he would play in the league again, and he certainly didn’t expect to get paid insane amounts of money. But he would be as wrong about himself as the rest of the NBA. The first contract that he signed with the Brooklyn Nets after that dreadful morning was a minimum deal worth $2.5 million over two seasons. Then he earned a substantial raise to stay with the Nets on another two-year deal worth $16 million. By the time that one expired and he became a free agent last week, the Nets had publicly declared that keeping him was their top priority.

That is how Joe Harris went from $2.5 million to $16 million to his latest, longest, unlikeliest contract: a four-year deal worth $75 million.

The remarkable thing about Harris’s four-year journey from doubting if he was good enough for the NBA to signing for $75 million is that it isn’t all that remarkable anymore.

What happened over the weekend in NBA free agency was a lesson in who gets valued and why—and it showed that the price of shooting has never been so high.

The Nets splurged for Harris. The Washington Wizards shelled out $80 million over five years for Davis Bertans. The Toronto Raptors paid $85 million over five years to Fred VanVleet.

Harris, Bertans and VanVleet are not star players. They are role players. The star players making the most amount of money permitted under the salary cap don’t negotiate so much as they sign a sheet of paper that makes them obscenely wealthy. But the role players are the ones who reveal deeper truths about the game and where it’s going.

“I hope all young hoopers at home are watching how the NBA is paying their players,” tweeted Jared Dudley, a free agent and the league’s resident sage.


The fiscal decisions of NBA teams made it clear that shooting is the single most valuable skill in the league today.

Among the free agents who managed to get paid in a depressed market were Danilo Gallinari ($61.5 million for three years), Harris and Bertans. This was not an example of the irrational exuberance that afflicts teams in free agency. It turned out to be prudent investing. There was a premium on those players because they do one thing as well as anybody on earth: shoot 3-pointers.

So do Seth Curry and Danny Green. Even though they were under contract, they were no less in demand. The first thing that Philadelphia 76ers president Daryl Morey did in his new job was trade for them.

The newest Sixers had something in common with Harris, Bertans and VanVleet besides their elite shooting. Each one of them was improperly valued by a market that would eventually correct itself.

Curry got overlooked despite sharing DNA with the greatest shooter ever. Green was cut twice and once played in Slovenia. Bertans was a second-round pick, and VanVleet went undrafted altogether. They would change as much as the league around them. But nobody would have predicted a $75 million deal in Harris’s future when he was traded and waived while still in the hospital recovering from surgery—especially not Harris.

He was unemployed and crashing in New York with a friend of a friend when he figured his odds of returning to the NBA were 50/50. There were others who might have thought Harris was being generous. The realist in him knew that not many second-round picks get second chances, but the optimist in him saw a future that others didn’t see. “I was thinking to myself that I might have another shot at it,” Harris said a few years ago, “just because of the emphasis that everyone is putting on shooting.”

The Nets were one of those teams. They signed him, developed him and re-signed him two years later as Harris quietly began positioning himself for the biggest payday of his life. His role took on even greater importance when Brooklyn landed Kevin Durant and Kyrie Irving and spacing became essential. The difference between a 35% shooter, a 40% shooter and a 45% shooter like Harris is a few more inches for Durant and Irving to operate. Harris would learn that a few inches on an NBA court is worth a whole lot of money.

The final year of his new contract amounts to a raise of 2,000% from his first season with the Nets—the equivalent of someone going from a salary of $50,000 to more than $1 million.

Harris also may have set the market for someone else. Miami Heat guard Duncan Robinson, who went from dreaming about Division-III college basketball not long ago to catching fire in the NBA Finals, was the best volume shooter in the league last season on what might be the best deal in the league this season.

The most improbable thing about the NBA’s most improbable player is that his $1.6 million salary is now a bargain. A league that values Davis Bertans and Joe Harris at $155 million is going to make any player with an even higher 3-point shooting percentage a very rich man. As it turns out, there is only one: Duncan Robinson is a free agent next summer.

>>> US Gapping Down

Gapping down
In reaction to earnings/guidance
:

  • BZUN -3.9%, DQ -2.5%

Other news:

  • SOLO -5.1% (files $200 mln mixed securities shelf offering)
  • CASI -2.7% (files for $150 mln mixed securities shelf offering)
  • VXX -2% (trading lower with US futures at session highs)
  • ZM -1.7% (work from home play out of favor today)
  • GEO -1.5% (announces decision by Federal Bureau of Prisons to not rebid its contract for rivers correctional facility)
  • MEG -1.4% (files for 4,920,052 share common stock offering by selling stockholders)
  • KIN -1.3% (completion of the upcoming pivotal efficacy study for KIND-030 is now expected in the first quarter of 2021 due to a delay in receiving appropriate vendor reagent material)
  • OPK -1% (stockholder Sian Capital issues open letter to OPKO's Board of Directors)